HONSUN (NANTONG) Co., Ltd. (hereinafter referred to as HONSUN or the Company) was established in January 2005 and is located in Nantong Economic and Technological Development Zone, Jiangsu Province. On April 20 of 2015, the company has been listed on the NEEQ (National Equities Exchange and Quotations), with stock abbreviation of HONSUN and stock code 832278. In June 2016, the company has been upgraded into innovation layer of the NEEQ, became one of the first listed companies as the selection and start public offering of stocks. On November 15 of 2021, the company became one of the first listed companies on the BSE (Beijing Stock Exchange).
Since its establishment, the company has been committed to home health management, mainly engaged in the research and development, production, and sales of homecare medical device and health care products. The main products are blood pressure monitoring, nebulizing therapy, home care, diagnosis device etc., such as blood pressure monitor, nebulizer , stethoscope, ENT，oral irrigator, nasal irrigator and so on.
Currently, HONSUN products have obtained many international certifications such as EU CE certified, US FDA approval, ISO 13485 and many certifications from the international market. These products have been exported to Europe, America, Asia, Africa and many global countries and regions. The products have strong competitiveness in the international market. In the domestic market, the company's self-owned brand "SCIAN" has also gained a certain market base and has been awarded honorary titles such as "Jiangsu Famous Brand Product" "Jiangsu Famous Trademark" and so on.
As a high-tech enterprise, HONSUN has won prizes for National Invention Patent and practical new type patents. What’s more, the "Homecare-based Precision Medical Instrument Engineering Technology Research Center" has been recognized as a provincial engineering technology center in Jiangsu, and the independently developed " Automated Production Technology for Membrane Sensor" has been listed as the National Torch Plan project. The "Mechanical Blood Pressure Monitor" was recognized as a specialized new product in Jiangsu Province in 2019, and the electronic stethoscope with AI-assisted analysis won the China Patent Design Excellence Award. In 2021, the company's "Heart Rate Calculation Method Based on Heart Sound" was granted an invention patent, and the medical industry standard "Stethoscope" (standard number: YY/T1035-2021) that the company participated in formulating was approved and released by the State Food and Drug Administration. In the same year, the company was recognized as a specialized and new "Little Giant" enterprise in Jiangsu Province. In 2022, the company was awarded the "National Intellectual Property Demonstration Enterprise of 2022".
In the future, the company will continue to focus on the home health management business, with cardiovascular and respiratory areas as its core strategic areas. Through continuous research and innovation, the company will continue to enrich its product types, improve product technology levels, innovate product functions and service modes, and vigorously develop smart healthcare. The company is committed to becoming an advanced enterprise in China's home health management field and a provider of intelligent home medical solutions, contributing to the health management of residents at home and abroad.
Founded in 2005
Covers an area of 50,000 m²
More than 600 employees
More than 100 patent applications